Komodo Health and University of Maryland School of Pharmacy partner for RWE research on social factors and COVID disruption in healthcare delivery

Komodo Health announces University of Maryland School of Pharmacy as latest collaborator to leverage its RWD platform and analytics to research the effects of the pandemic and social determinants on healthcare provision.

---

University of Maryland School of Pharmacy (UMSOP) is the latest in a series of healthcare and life sciences bodies to form a synergistic partnership with Komodo Health to power the next generation of RWE research using Komodo’s RWD platform and suite of analytics. Primary topics to be investigated include pandemic-driven disruptions to healthcare delivery, the impact of policy on healthcare access, and social determinants of health.

Komodo Health is a RWD and technology platform company that is combining the USA’s most extensive research-grade database of de-identified patient encounters, the Komodo Healthcare Map™, and suite of proprietary, AI-powered, analytic software modules to propel RWE research forward. For example, its application Sentinel can be used to rapidly create complex patient cohorts to fast-track patient recruitment, and select clinical trial sites based on data, and also build advanced algorithms on top of those patient cohorts to unlock precise insights and evidence.

Previous collaborators include Pfizer, who utilized Komodo’s platform to elucidate the real-world usage patterns of monoclonal antibody therapies in cancer treatment, and Harvard Medical School who studied the potential link between a common osteoporosis medication and COVID-19 risks.

UMSOP clinicians and researchers will utilize Komodo’s platform across a range of health conditions. Two initial focuses of the collaboration will be determining the impact of public policy on healthcare provision and extending the industry’s understanding of social determinants of health and outcomes. Arif Nathoo, CEO and Co-Founder of Komodo Health, said, “We’re proud to support the University of Maryland School of Pharmacy in advancing research that could help inform public health policy, drive new strategies for disease management, and support the broader scientific community in understanding and addressing disparities in care to make a meaningful difference for the entire population.”

Another principal focus will be investigation of the ripple effects of the COVID-19 pandemic across the health system and the ensuing disruption in access to healthcare services and treatment. Speaking of the pandemic, UMSOP Associate Professor Joey Mattingly said, “The past two and a half years have illuminated — and exacerbated — the role of social factors in access to and quality of care; with Komodo’s research-grade insights and technology, we will now have unprecedented visibility into the full range of factors that contribute to healthcare outcomes, including the historically overlooked role of social determinants.”